Despite President Trump’s assertions that his deals with drugmakers would lower prescription drug prices, a Senate Democratic report indicates prices have continued to rise, with some medications experiencing sharp increases. Companies that entered into agreements with the administration have reportedly raised the cost of hundreds of drugs and launched new ones at an average annual price of $353,000. These price hikes affect critical treatments such as gene therapies and cancer medications, while the companies themselves have seen significant profit increases. The report raises concerns about the effectiveness and transparency of the administration’s pricing strategies, with critics arguing that these efforts may have primarily benefited drug companies rather than consumers.
Read More
Britain faces potential medicine shortages, including painkillers and cancer treatments, within weeks if the Iran conflict persists. Disrupted supply chains for crucial raw materials, coupled with increased air and sea freight costs due to the closure of key shipping routes, are straining pharmaceutical deliveries. Experts warn that if the situation deteriorates, drug prices could also rise, ultimately impacting patients and public health systems.
Read More
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump. This is a real head-scratcher, isn’t it? We’re hearing about drug prices going up, even though there was supposed to be some sort of intervention. It’s almost like the opposite of what was claimed is happening. It’s as though there was talk, maybe even a “stern talking to,” but the actual outcome is a hike in prices.
It’s tempting to think that maybe we were misled, or that the numbers weren’t quite what they seemed. Remember those claims about significant price reductions? Well, when you crunch the numbers, the reality is a little different.… Continue reading
Texas AG sues makers of Tylenol over hiding alleged links to autism. This is certainly going to be a case to watch, and already it feels like it’s going to be a wild ride. The Texas Attorney General, Ken Paxton, is bringing the lawsuit, and the core of the issue revolves around an alleged connection between Tylenol and autism. It’s important to remember that this legal action comes with a significant burden of proof. The state, and in particular Paxton, will have to provide solid evidence to convince a judge that this link actually exists and that the makers of Tylenol deliberately hid information about it.… Continue reading
China has eliminated its 30% import duty on Indian pharmaceutical products, allowing for duty-free exports. This strategic move comes in the wake of the US imposing a 100% tariff on pharma imports, offering Indian companies an alternative market. This change is expected to significantly boost Indian pharma exports, potentially increasing them by billions of dollars while providing Indian companies a level playing field in China’s large healthcare market. Trade analysts anticipate this will balance trade relations and strengthen India’s global healthcare supply chain.
Read More
President Trump announced an executive order aiming to slash US prescription drug prices by 30-80%, potentially impacting global markets. This aggressive move involves pressuring European countries to increase their drug prices and threatening trade sanctions against uncooperative nations. The order seeks to lower prices to global minimums, forcing pharmaceutical companies to significantly reduce their profits and potentially reducing investment in research and development. This action is facing opposition from the pharmaceutical industry and analysts question its feasibility.
Read More
President Trump’s latest executive order, aiming to align U.S. prescription drug prices with those of other developed nations, mirrors a previously blocked attempt and faces similar legal challenges. Senators Sanders and Wyden, along with Representative Khanna, argue that legislative action, rather than unilateral executive orders, is the only viable path to meaningful price reform. They cite the likelihood of pharmaceutical industry legal challenges and propose bipartisan legislation to achieve comparable drug pricing. This approach contrasts with Trump’s past actions, including delaying Medicare price negotiations.
Read More
Trump’s recent executive order calling for broad drug price cuts has sparked a flurry of reactions, ranging from cautious optimism to outright skepticism. The order promises to give drugmakers price targets within the next thirty days, threatening further action if “significant progress” isn’t made within six months. This sounds decisive, yet history suggests a pattern of similar pronouncements followed by inaction.
The timing of this executive order is particularly intriguing. It comes on the heels of the removal of a Biden-era policy that capped insulin prices at $30, a move that effectively raised prices for many patients. Now, the same administration is presenting this new initiative as a solution, creating a sense of déjà vu for those who remember similar, ultimately fruitless, attempts during Trump’s first term.… Continue reading
In response to a national security investigation launched April 1st, President Trump plans to announce pharmaceutical tariffs within the next two weeks. These tariffs aim to incentivize the repatriation of pharmaceutical production to the United States, significantly impacting countries like Britain and Ireland, which boast large pharmaceutical trade surpluses with the U.S. The impending tariffs are particularly concerning for major UK-based pharmaceutical companies like GSK and AstraZeneca, who have already engaged in intense lobbying efforts to mitigate potential losses. While a previous 10% tariff on most imports was temporarily averted for pharmaceuticals, this new announcement suggests a more aggressive protectionist strategy.
Read More
Drugmakers are set to raise prices on over 250 medications in the US starting January 1st. This news has unsurprisingly sparked widespread outrage and frustration, especially given the timing – just as many are facing economic challenges. The increases, it’s important to note, apply to list prices. These are the prices before rebates and discounts are factored in, meaning pharmacy benefit managers and other intermediaries will likely still receive significant concessions while consumers bear the brunt of the increase.
This raises immediate questions about fairness and accessibility. Many have voiced concerns that those who rely on these medications for chronic or rare conditions will struggle to afford the higher costs, potentially facing life-altering consequences.… Continue reading
John Q. Hosedrinker 
Matt Underwood